RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
Benjamin Solomon, Lavinia Tan, W. Marston Linehan, Stephen Q. Wong, Sebastian Hollizeck, Kevin Ebata, Brian B. Tuch, Satoshi Yoda, Justin F. Gainor, Lecia V. Sequist, Geoffrey R. Oxnard, Oliver Gautschi, Alexander Drilon, Vivek Subbiah, Christine Khoo, Edward Y. Zhu, Michele Nguyen, Dahlia Henry, Kevin R. Condroski, Gabrielle R. Kolakowski, Eliana B Gómez, Joshua A. Ballard, Andrew T. Metcalf, James F. Blake, Sarah‐Jane Dawson, Wayne Blosser, Louis F. Stancato, Barbara J. Brandhuber, Steve Andrews, Bruce G. Robinson, S. Michael Rothenberg
Topics & Concepts
MedicineCancer researchProto-Oncogene Proteins c-retCrizotinibMutationTyrosine kinaseVandetanibMultiple endocrine neoplasia type 2Medullary thyroid cancerCabozantinibCancerLung cancerGermline mutationPathologyInternal medicineThyroid cancerGeneBiologyGeneticsReceptorMalignant pleural effusionGlial cell line-derived neurotrophic factorVEGF receptorsNeurotrophic factorsThyroid Cancer Diagnosis and TreatmentLung Cancer Treatments and MutationsAdvances in Oncology and Radiotherapy